Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy

References

• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by world health organization subtypes. CA Cancer J Clin. 2016;66(6):443–459. doi:10.3322/caac.21357
   PubMed Web of Science ®Google Scholar
• Perry AM, Diebold J, Nathwani BN, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international Non-Hodgkin lymphoma classification project. Haematologica. 2016;101(10):1244–1250. doi:10.3324/haematol.2016.148809
   PubMed Web of Science ®Google Scholar
• Freedman A. Follicular lymphoma: 2015 update on diagnosis and management. Am J Hematol. 2015;90(12):1171–1178. doi:10.1002/ajh.24200
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;33(23):2516–2522. doi:10.1200/JCO.2014.59.7534
   PubMed Web of Science ®Google Scholar
• Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74. doi:10.1038/s41408-020-00340-z
   PubMed Web of Science ®Google Scholar
• Richardson NC, Kasamon Y, Pazdur R, et al. The Saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 2022;23(5):563–566. doi:10.1016/S1470-2045(22)00200-5
   PubMed Web of Science ®Google Scholar
• Mikhael J, Fowler J, Shah N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. J Clin Oncol Oncol Pract. 2022;18(12):800–807. doi:10.1200/OP.22.00315
   PubMedGoogle Scholar
• Gajra A, Zalenski A, Sannareddy A, et al. Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice. Pharmaceut Med. 2022;36(3):163–171. doi:10.1007/s40290-022-00428-w
   PubMed Web of Science ®Google Scholar
• Jommi C, Bramanti S, Pani M, et al. CAR T-cell therapies in Italy: patient access barriers and recommendations for health system solutions. Front Pharmacol. 2022;13:915342. doi:10.3389/fphar.2022.915342
   PubMed Web of Science ®Google Scholar
• Assouline SE, Kim WS, Sehn LH, et al. Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial. Blood. 2020;136(Supplement 1):42–44. doi:10.1182/blood-2020-135839
   Web of Science ®Google Scholar
• Sun LL, Ellerman D, Mathieu M, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015;7(287):287ra70. doi:10.1126/scitranslmed.aaa4802
   PubMed Web of Science ®Google Scholar
• Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055–1065. doi:10.1016/S1470-2045(22)00335-7
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. 2022 [cited 2023 Jan 6]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma.
   Google Scholar
• Kang C. Mosunetuzumab: first approval. Drugs. 2022;82(11):1229–1234. doi:10.1007/s40265-022-01749-5
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–3905. doi:10.1200/JCO.2017.75.4648
   PubMed Web of Science ®Google Scholar
• Ghione P, Palomba ML, Patel AR, et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 2022;140(8):851–860. doi:10.1182/blood.2021014375
   PubMed Web of Science ®Google Scholar
• Carrigan G, Whipple S, Capra WB, et al. Using electronic health records to derive control arms for early phase single-arm lung cancer trials: proof-of-concept in randomized controlled trials. Clin Pharmacol Ther. 2020;107(2):369–377. doi:10.1002/cpt.1586
   PubMed Web of Science ®Google Scholar
• Schröder C, Lawrance M, Li C, et al. Building external control arms from patient-level electronic health record data to replicate the randomized IMblaze370 control arm in metastatic colorectal cancer. J Clin Oncol Clin Cancer Inform. 2021;5:450–458. doi:10.1200/CCI.20.00149
   PubMed Web of Science ®Google Scholar
• Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40(5):481–491. doi:10.1200/JCO.21.00931
   PubMed Web of Science ®Google Scholar
• Budde LE, Sehn LH, Matasar MJ, et al. Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: pivotal results from a phase I/II study. Blood. 2021;138(Supplement 1):127–127. doi:10.1182/blood-2021-145872
   Google Scholar
• Ma X, Long L, Moon S, et al. Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron health. SEER, and NPCR. medRxiv. 2020; doi:10.1101/2020.03.16.20037143
   Google Scholar
• Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv. 2020; doi:10.48550/arXiv.2001.09765
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas V.4.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed January 18, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas V.5.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed August 15, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Ma X, Bellomo L, Magee K, et al. Characterization of a real-world response variable and comparison with RECIST-based response rates from clinical trials in advanced NSCLC. Adv Ther. 2021;38(4):1843–1859. doi:10.1007/s12325-021-01659-0
   PubMed Web of Science ®Google Scholar
• Dugoff EH, Schuler M, Stuart EA. Generalizing observational study results: applying propensity score methods to complex surveys. Health Serv Res. 2014;49(1):284–303. doi:10.1111/1475-6773.12090
   PubMed Web of Science ®Google Scholar
• Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods. 2010;15(3):234–249. doi:10.1037/a0019623
   PubMed Web of Science ®Google Scholar
• Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S84–S90.e1. doi:10.1016/j.jclinepi.2013.01.013
   PubMed Web of Science ®Google Scholar
• VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268–274. doi:10.7326/M16-2607
   PubMed Web of Science ®Google Scholar
• R-Project. The R Project for Statistical Computing. 2023 [cited 2023 Jan 6]. Available from: https://www.R-project.org/.
   Google Scholar
• Prescribing information for ALIQOPA (copanlisib). 2017 cited 2023 Jan 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf.
   Google Scholar
• Prescribing information for TAZVERIK (tazemetostat). 2020 [cited 2023 Jan 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf.
   Google Scholar
• Prescribing information for YESCARTA (axicabtagene ciloleucel). 2022 [cited 2023 Jan 6]. Available from: https://ce.mayo.edu/sites/default/files/yescarta-pi.pdf.
   Google Scholar
• Prescribing information for KYMRIAH (tisagenlecleucel). 2022 cited 2023 Jan 6]. Available from: https://www.novartis.com/us-en/sites/novartis_us/files/kymriah.pdf.
   Google Scholar
• Cheson BD. The international harmonization project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5):841–854. doi:10.1016/j.hoc.2007.06.011
   PubMed Web of Science ®Google Scholar